BridgeMD
New treatment option for Endometrial Cancer
Official title Biomarker Guided Treatment in Gynaecological Cancer
ClinicalTrials.gov ID: NCT02543710
What this study is testing
What is Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer?
Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer is an investigational medicine, given as an once-weekly, being studied as a potential treatment for endometrial cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 95, women only
You may be able to join if
- part 1:
- All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.
You likely can't join if
- part 1:
- Patients who do not have endometrial cancer
- Patients who will or cannot give informed consent (including language barriers)
- Patients \<18 years of age
- Patients who will not get surgical treatment for their endometrial cancer Inclusion criteria part 2:
- Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment...
See the full eligibility criteria
- part 1:
- All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.
- part 1:
- Patients who do not have endometrial cancer
- Patients who will or cannot give informed consent (including language barriers)
- Patients \<18 years of age
- Patients who will not get surgical treatment for their endometrial cancer Inclusion criteria part 2:
- Patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with...
- Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence. Exclusion criteria part 2:
- Patients not suffering from endometrial or epithelial ovarian cancer
- Patients \<18 years of age
- Patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre
- Patients who cannot or do not want to give informed consent (including language barriers)
The study team makes the final eligibility decision.
Where it's taking place
- Nijmegen, Netherlands
- Bergen, Hordaland, Norway
- Ålesund, Norway
- Førde, Norway
- Kristiansand, Norway
- Oslo, Norway
- Stavanger, Norway
- Trondheim, Norway
- Lublin, Poland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 95 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nijmegen, Netherlands; Bergen, Hordaland, Norway; Ålesund, Norway; Førde, Norway; Kristiansand, Norway; Oslo, Norway and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.